Veritas Signs Deal with Sativa Investments

Veritas Pharma (CSE:VRT) announced an intellectual property sharing agreement with Sativa Investments PLC (NEX:SATI).

As quoted in the press release:

Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead selection to assist Sativa’s application to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing license.

As previously announced on May 21, 2018, Sativa subscribed on a non-brokered private placement basis to Common Shares of Veritas for gross proceeds to the Company of C$ 0.2 million.

Dr. Lui Franciosi, Chief Executive Officer of Veritas Pharma, stated: “Veritas is pleased to work together with Sativa on IP, as we work to develop therapeutic cannabis solutions in anticipation of future changes in legislation for controlling the use of cannabis that will place our partnership well positioned for UK and European expansion.”

Click here to read the full press release.

Source: globenewswire.com